[
  {
    "ts": null,
    "headline": "My Top 10 Dividend-Paying Buy-And-Hold Stocks For 2025",
    "summary": "Top 10 dividend-paying buy-and-hold stocks for your portfolio, offering both stability and growth potential over the next decade. Click here to find out more.",
    "url": "https://finnhub.io/api/news?id=194e8b0b17f43cd50d323b1dd1fe870f097d08c546eb01ad6383bb187ffb6fd9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736186400,
      "headline": "My Top 10 Dividend-Paying Buy-And-Hold Stocks For 2025",
      "id": 132292286,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157681450/image_157681450.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Top 10 dividend-paying buy-and-hold stocks for your portfolio, offering both stability and growth potential over the next decade. Click here to find out more.",
      "url": "https://finnhub.io/api/news?id=194e8b0b17f43cd50d323b1dd1fe870f097d08c546eb01ad6383bb187ffb6fd9"
    }
  },
  {
    "ts": null,
    "headline": "Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?",
    "summary": "Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.",
    "url": "https://finnhub.io/api/news?id=8da5ca21c4d9e135574b401e2748e362a30cd9b10080f704dcc969f266d84cea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736182440,
      "headline": "Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?",
      "id": 132291051,
      "image": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.",
      "url": "https://finnhub.io/api/news?id=8da5ca21c4d9e135574b401e2748e362a30cd9b10080f704dcc969f266d84cea"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors despite losses on the day",
    "summary": "Johnson & Johnson stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=15c0f9426bfc94a24b148dae440f49c5e1593b5979843c2691063391be6e825f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736181060,
      "headline": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "id": 132321992,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=15c0f9426bfc94a24b148dae440f49c5e1593b5979843c2691063391be6e825f"
    }
  },
  {
    "ts": null,
    "headline": "How Are Companies Using AI Agents? Here’s a Look at Five Early Users of the Bots",
    "summary": "Artificial intelligence agents have emerged as one of the most exciting aspects of generative AI for business because they take chatbots to the next level, performing complex tasks without help from humans.",
    "url": "https://finnhub.io/api/news?id=82463a18c931a8e30426aab9207a1c9874162652c790332f5db35c4bc2d22a95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736164800,
      "headline": "How Are Companies Using AI Agents? Here’s a Look at Five Early Users of the Bots",
      "id": 132286650,
      "image": "",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Artificial intelligence agents have emerged as one of the most exciting aspects of generative AI for business because they take chatbots to the next level, performing complex tasks without help from humans.",
      "url": "https://finnhub.io/api/news?id=82463a18c931a8e30426aab9207a1c9874162652c790332f5db35c4bc2d22a95"
    }
  },
  {
    "ts": null,
    "headline": "4 closely watched FDA approval dates in 2025 from J&J, Novo and more",
    "summary": "A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.",
    "url": "https://finnhub.io/api/news?id=9a2673d11e6ea361b6ae6737cb4982b70549984a0aad6eaf507240bc6e27f990",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736150400,
      "headline": "4 closely watched FDA approval dates in 2025 from J&J, Novo and more",
      "id": 132287231,
      "image": "https://imgproxy.divecdn.com/yfhzkXcEGqbsAHhWfLq214WnvHcsbag9x_XOwJRUAFI/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjQ0Njc5MTQuanBn.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.",
      "url": "https://finnhub.io/api/news?id=9a2673d11e6ea361b6ae6737cb4982b70549984a0aad6eaf507240bc6e27f990"
    }
  }
]